Prijeđi na sadržaj

Metilfenidat

Izvor: Wikipedija
Metilfenidat
(IUPAC) ime
metil fenil(piperidin-2-il)acetat
Klinički podaci
Robne marke Concerta, Methylin, Ritalin, Equasym XL
AHFS/Drugs.com Monografija
MedlinePlus a682188
Identifikatori
CAS broj 113-45-1
ATC kod N06BA04
PubChem[1][2] 4158
DrugBank DB00422
ChemSpider[3] 4015
UNII 207ZZ9QZ49 DaY
KEGG[4] D04999 DaY
ChEBI CHEBI:6887 DaY
ChEMBL[5] CHEMBL796 DaY
Hemijski podaci
Formula C14H19NO2 
Mol. masa 233,30 g/mol
SMILES eMolekuli & PubHem
Fizički podaci
Tačka topljenja 214 °C (417 °F)
Farmakokinetički podaci
Bioraspoloživost ~30% (opseg: 11–52%)
Vezivanje za proteine plazme 10-33%
Metabolizam Hepatički (80%)
Poluvreme eliminacije 3-4 sata (d-enantiomer), 1-3 sata (l-enantiomer)
Izlučivanje Urin (90%)
Farmakoinformacioni podaci
Licenca

US FDA:link

Trudnoća B3(AU) C(US)
Pravni status Droga (S8) (AU) Schedule III (CA) ? (UK) Schedule II (SAD)
Opojna droga Moderate
Način primene Oralno, transdermalno

Metilfenidat (Concerta, Methylin, Ritalin, Equasym XL) je psihostimulišući lek i supstituisani fenetilamin koji je odobren tretman hiperkinetičkog poremećaja (ADHD), posturalnog ortostatskog tahikardnog sindroma i narkolepsije. Originalni patent je posedovalo preduzeće CIBA. FDA je odobrila ovaj lek 1955. za tretiranje hiperaktivnosti. Propisivan je od početka 1960-tih. Nivo proskripcija je znatno porastao tokom 1990-tih kad je ADHD dijagnoza postala šire prihvaćena.[6][7]

Reference

[uredi | uredi kod]
  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  6. When Was Ritalin Invented?, citing Lawrence Diller: "Running on Ritalin", 1999
  7. Lange, K.W. et al.: The history of attention deficit hyperactivity disorder. In: Attention Deficit Hyperactivity Disorders, 2(4):241-55. doi: 10.1007/s12402-010-0045-8.

Literatura

[uredi | uredi kod]
  • Gardiner Harris (3. 2. 2012.). „F.D.A. Finds Short Supply of Attention Deficit Drugs”. The New York Times. Arhivirano iz originala na datum 2012-02-03. Pristupljeno 3. 2. 2012. »(Archived by WebCite® at [1] 
  • L. Alan Sroufe (28. 1. 2012.). „Ritalin Gone Wrong - Opinion - Children\'s A.D.D.Drugs Don\'t Work Long-Term”. The New York Times. Arhivirano iz originala na datum 2012-02-03. Pristupljeno 3. 2. 2012. »(Archived by WebCite® at [2] 
  • {Cite journal|author=Lakhan SE, Hagger-Johnson GE |title=The impact of prescribed psychotropics on youth |journal=Clin Pract Epidemol Ment Health |volume=3 |page=21 |year=2007 |pmid=17949504 |pmc=2100041 |doi=10.1186/1745-0179-3-21 |url=http://www.cpementalhealth.com/content/3/1/21 |issue=1}}
  • Drug Enforcement Administration, Greene, S.H., Response to CHADD petition concerning Ritalin, 1995, August 7. Washington, DC: DEA, U.S. Department of Justice.
  • New Research Helps Explain Ritalin's Low Abuse Potential When Taken As Prescribed – 09/29/1998 Arhivirano 2010-05-28 na Wayback Machine-u. Nih.gov. Retrieved on 2011-04-30.
  • Weinberg WA, Brumback RA (1992). „The myth of attention deficit-hyperactivity disorder: symptoms resulting from multiple causes”. J. Child Neurol. 7 (4): 431–45; discussion 446–61. DOI:10.1177/088307389200700420. PMID 1469255. 
  • Presenters: Joan Hamburg and Dr. Harold Koplewicz (3. 2. 2012.). "Are we over medicating our kids? Speaking with Dr. Harold Koplewicz of @ChildMindDotOrg". Joan Hamburg Show (Radio). 1:11 into the complete two part show - 2 minutes in. WOR Radio Network. WOR. Archived from the original on 2012-12-03. Retrieved 2014-04-05. {{cite episode}}: Check date values in: |airdate= (help); External link in |transcripturl= (help); Unknown parameter |city= ignored (|location= suggested) (help); Unknown parameter |transcripturl= ignored (|transcript-url= suggested) (help) „Archive copy”. Arhivirano iz originala na datum 2012-12-03. Pristupljeno 2014-04-05. 

</ref>

Spoljašnje veze

[uredi | uredi kod]